blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2977372

EP2977372 - POLYMORPHS OF FEBUXOSTAT [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  20.04.2023
Database last updated on 03.04.2025
FormerThe patent has been granted
Status updated on  05.04.2019
FormerGrant of patent is intended
Status updated on  19.11.2018
FormerExamination is in progress
Status updated on  14.04.2017
FormerRequest for examination was made
Status updated on  25.11.2016
Most recent event   Tooltip21.04.2023Revocation of patentpublished on 24.05.2023  [2023/21]
Applicant(s)For all designated states
SANDOZ AG
Lichtstrasse 35
4056 Basel / CH
[2016/04]
Inventor(s)01 / HOTTER, Andreas
c/o Sandoz GmbH, Biochemiestr. 10
6250 Kundl / AT
02 / GRIESSER, Ulrich
c/o University of Innsbruck, Institut für
Pharmazie, Innrain 52 a
6020 Innsbruck / AT
03 / ADAMER, Verena
c/o Sandoz GmbH
Biochemiestr. 10
6250 Kundl / AT
04 / LANGES, Christoph
c/o University of Innsbruck, Institut für
Pharmazie, Innrain 52 a
6020 Innsbruck / AT
 [2019/24]
Former [2019/18]01 / HOTTER, Andreas
c/o Sandoz GmbH, Biochemiestr. 10
6250 Kundl / AT
02 / GRIESSER, Ulrich
c/o University of Innsbruck, Institut für
Pharmazie, Innrain 52 a
6020 Innsbruck / AT
03 / ADAMER, Verena
c/o Sandoz GmbH
Blochemiestr. 10
6250 Kundl / AT
04 / LANGES, Christoph
c/o University of Innsbruck, Institut für
Pharmazie, Innrain 52 a
6020 Innsbruck / AT
Former [2016/04]01 / HOTTER, Andreas
c/o Sandoz GmbH, Biochemiestr. 10
6250 Kundl / AT
02 / GRIESSER, Ulrich
c/o University of Innsbruck, Institut für
Pharmazie, Innrain 52 a
6020 Innsbruck / AT
03 / ADAMER, Verena
c/o University of Innsbruck, Institut für
Pharmazie, Innrain 52 a
6020 Innsbruck / AT
04 / LANGES, Christoph
c/o University of Innsbruck, Institut für
Pharmazie, Innrain 52 a
6020 Innsbruck / AT
Representative(s)Prüfer & Partner mbB Patentanwälte · Rechtsanwälte
Sohnckestraße 12
81479 München / DE
[2016/04]
Application number, filing date15181097.524.06.2011
[2016/04]
Priority number, dateEP2010016734425.06.2010         Original published format: EP 10167344
[2016/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2977372
Date:27.01.2016
Language:EN
[2016/04]
Type: B1 Patent specification 
No.:EP2977372
Date:08.05.2019
Language:EN
[2019/19]
Search report(s)(Supplementary) European search report - dispatched on:EP04.11.2015
ClassificationIPC:C07D277/56, A61K31/425, A61P19/06
[2016/04]
CPC:
C07D277/56 (EP,US); A61P19/06 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/36]
Former [2016/04]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:POLYMORPHE VON FEBUXOSTAT[2016/04]
English:POLYMORPHS OF FEBUXOSTAT[2016/04]
French:POLYMORPHES DE FEBUXOSTAT[2016/04]
Examination procedure26.07.2016Amendment by applicant (claims and/or description)
26.07.2016Examination requested  [2016/36]
13.04.2017Despatch of a communication from the examining division (Time limit: M06)
10.10.2017Reply to a communication from the examining division
20.03.2018Despatch of a communication from the examining division (Time limit: M04)
20.07.2018Reply to a communication from the examining division
23.08.2018Despatch of a communication from the examining division (Time limit: M02)
17.10.2018Reply to a communication from the examining division
27.11.2018Communication of intention to grant the patent
28.11.2018Observations by third parties
27.03.2019Fee for grant paid
27.03.2019Fee for publishing/printing paid
27.03.2019Receipt of the translation of the claim(s)
29.04.2019Request for correction of the decision to grant filed
Parent application(s)   TooltipEP11727454.8  / EP2585445
Opposition(s)Opponent(s)01  10.05.2019  24.06.2019  ADMISSIBLE
Alfred E. Tiefenbacher (GmbH & Co. KG)
Van-der-Smissen-Straße 1
22767 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 [2019/31]
deletedDeletion: Legal effect of rejection of opposition [ N /P ]
21.02.2020Invitation to proprietor to file observations on the notice of opposition
19.05.2020Reply of patent proprietor to notice(s) of opposition
25.02.2021Date of oral proceedings
09.03.2021Despatch of minutes of oral proceedings
09.03.2021Date of despatch of rejection of opposition
30.01.2023Legal effect of revocation of patent [2023/21]
21.04.2023Despatch of communication that the patent will be revoked
Appeal following opposition06.05.2021Appeal received No.  T0546/21
06.05.2021Payment of appeal fee
08.07.2021Statement of grounds filed
31.01.2023Result of appeal procedure: revocation of the patent
21.04.2023Despatch of the decision of the Board of Appeal
30.01.2023Date of oral proceedings
Fees paidRenewal fee
14.08.2015Renewal fee patent year 03
14.08.2015Renewal fee patent year 04
14.08.2015Renewal fee patent year 05
10.06.2016Renewal fee patent year 06
16.06.2017Renewal fee patent year 07
12.06.2018Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.06.2011
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
MK08.05.2019
MT08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE24.06.2019
LU24.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
[2022/31]
Former [2021/34]HU24.06.2011
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
MT08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE24.06.2019
LU24.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
Former [2021/32]HU24.06.2011
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE24.06.2019
LU24.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
Former [2021/31]AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE24.06.2019
LU24.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
Former [2021/26]AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE24.06.2019
LU24.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/25]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE24.06.2019
LU24.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/21]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE24.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/17]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/14]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/11]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/10]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/09]AL08.05.2019
CZ08.05.2019
DK08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/51]AL08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/50]AL08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RS08.05.2019
SE08.05.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/49]AL08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
NL08.05.2019
SE08.05.2019
NO08.08.2019
PT08.09.2019
Former [2019/48]ES08.05.2019
FI08.05.2019
LT08.05.2019
SE08.05.2019
NO08.08.2019
PT08.09.2019
Former [2019/47]ES08.05.2019
FI08.05.2019
LT08.05.2019
NO08.08.2019
Documents cited:Search[XD]EP1020454  (TEIJIN LTD [JP]) [XD] 1-3 * Paragraphs [0011], [0015], [0019], [0036]; claims; figure 2. *;
 [XD]US2005043375  (IWAI MICHIO [JP], et al) [XD] 4-7,15 * Claims 3, 15; paragraphs [0003], [0023-24], [0032], [0051], [0055-57]. *;
 [XP]CN101817801  (BEIJING HONGHUI MEDICAL TECHNOLOGY CO LTD) [XP] 1-3 * Page 4, paragraphs 0023-0026; and figure 2. *;
 [XPI]WO2010144685  (TEVA PHARMA [IL], et al) [XP] 1-4,6,7,15 * Abstract; claims 2, 4 15-19; figure 8. * [I] 5;
 [E]EP2399911  (SANDOZ AG [CH]) [E] 1-15 * The whole document. Cited as priority document of the present application. *;
 [E]EP2585445  (SANDOZ AG [CH]) [E] 1-15 * See claims. Cited as granted parent application of the present divisional application. *
 [L]  - BRITTAIN, "SPECTRAL METHODS FOR THE CHARACTERIZATION OF POLYMORPHS AND SOLVATES", J. PHARM. SCI., (19970401), vol. 86, no. 4, doi:10.1021/JS960238E, ISSN 0022-3549, pages 405 - 412, XP001204463 [L] 1-15 * Page 405, right column, paragraph 1. Cited as common general knowledge. *

DOI:   http://dx.doi.org/10.1021/js960238e
 [L]  - Ivanisevic et al., "Uses of X-Ray Powder Diffraction In the Pharmaceutical Industry", Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing, doi:10.1002/9780470571224.pse414, (20100625), pages 1 - 42, URL: http://onlinelibrary.wiley.com/store/10.1002/9780470571224.pse414/asset/pse414.pdf?v=1&t=gsssyq3r&s=316303db60793cc15e15c87a2d3b6ec61b51414e, (20110920), XP055007590 [L] 1-15 * Page 35, section 4.2.3: paragraphs 1 and 2. Cited as common general knowledge. *

DOI:   http://dx.doi.org/10.1002/9780470571224.pse414
 [L]  - Bernstein, Polymorphism in Molecular Crystals, Oxford, Clarendon Press, (2002), pages 125 - 131, ISBN 0198506058, XP002608621 [L] 1-15 * The whole document. for instance, page 125, last paragraph. Cited as common general knowledge. *
 [L]  - CAIRA, "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, (19980101), vol. 198, doi:10.1007/3-540-69178-2_5, pages 163 - 208, XP001156954 [L] 1-14 * Page 164; paragraph bridging pages 165-166; chapter 3.1. Cited as common general knowledge. *

DOI:   http://dx.doi.org/10.1007/3-540-69178-2_5
Examination   - Eder, "Opposition against European Patent 2 399 911 B1, pages 1-23 plus annexes 1 and 2", European Patent Register, (20160518), URL: https://register.epo.org/application?d-16544-s=1&d-16544-o=2&tab=doclist&lng=en&number=EP10167344, (20170404), XP055361414
    - Eder, "Opposition against European Patent 2 399 911 B1, pages 1-6 plus annex 3", (20171130), pages 1 - 8, URL: https://register.epo.org/application?number=EP10167344&lng=en&tab=doclist, (20180314), XP055459267
by applicantEP1020454
 US7361676
 US2005043375
otherEP2585445
 EP2399911
 US7361676
 US2005043375
 EP1020454
 WO9965885
 EP2585445
 EP2399911
    - "Polymorphism in Pharmaceutical Solids", BRITTAIN, H. G., Drugs and the pharmaceutical Sciences, Marcel Dekker, Inc., (19990000), vol. 95
    - GIRON, D., "Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates", Thermochimica Acta, (19950000), vol. 248, doi:doi:10.1016/0040-6031(94)01953-E, pages 1 - 59, XP002101808

DOI:   http://dx.doi.org/10.1016/0040-6031(94)01953-E
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.